Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03413930

Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer

Single-center Prospective Randomized Controlled Study of the Transanal Total Mesorectal Excision Versus Laparoscopic Total Mesorectal Excision in Rectal Cancer

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Ruijin Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This study is designed to evaluate the short-term and long-term results after transanal total mesorectal excision (TaTME) for the resection of mid and low rectal cancer compared with laparoscopic total mesorectal excision(LaTME).

Detailed description

Colorectal cancer (CRC) including rectal cancer is one of the most common gastrointestinal tumors, and its incidence is third in the world. At present,surgical treatments is the main means to cure CRC. Total mesorectal excision (TME) is the gold standard for rectal cancer surgery. Transanal total mesorectal excision (TaTME) was recently developed to overcome technical difficulties associated with LaTME and open TME. Most reports are retrospective studies. More studies, especially large-scale, randomized controlled trials are needed to establish the best indications for TaTME for mid and low rectal cancer.This is a single-center, open-label, non-inferiority, randomized controlled trial. A total of 120 eligible patients will be randomly assigned to TaTME group and LaTME group at a 1:1 ratio. It will provide valuable clinical evidence for the objective assessment of the oncological safety,efficacy and potential benefits of TaTME compared with LaTME for mid and low rectal cancer.

Conditions

Interventions

TypeNameDescription
PROCEDURETransanal total mesorectal excisionPatients undergo transanal total mesorectal excision.(assisted by laparoscopy to control the IMA)
PROCEDURELaparoscopic total mesorectal excisionPatients undergo Laparoscopic total mesorectal excision.

Timeline

Start date
2019-06-01
Primary completion
2021-03-01
Completion
2026-03-01
First posted
2018-01-29
Last updated
2020-02-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03413930. Inclusion in this directory is not an endorsement.